Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.
Kazuki MaesakaRyotaro SakamoriRyoko YamadaYuki TahataYasuharu ImaiKazuyoshi OhkawaMasanori MiyazakiEiji MitaToshifumi ItoHideki HagiwaraTakayuki YakushijinTakahiro KodamaHayato HikitaTomohide TatsumiTetsuo TakeharaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2021)
Hyperprogressive disease was observed in 10.2% of HCC patients receiving atezolizumab plus bevacizumab, and an elevated NLR at baseline had an increased risk of HPD.